Analyst action: Genesco, Healthways
Piper Jaffray analyst Jeff Klinefelter is impressed with Genesco's strong holiday sales and has raised his estimates for the coming fiscal year accordingly. But he's sticking with his 'overweight' rating and $42 target for Genesco shares (Ticker: GCO), which have risen 16 percent in the past three months. It's time to bail on Healthways shares, says Madison Williams analyst James Kumpel, who has cut his rating on the Franklin-based wellness firm to 'sell' and lowered his target to $9.50. Healthways shares (Ticker: HWAY) are off more than 2 percent this morning at about $10.80. Jan 14, 2011 10:46 AM
Healthways' German contract to end
Pilot program's demise 'a black eye' to international growth plans
Sep 30, 2010 3:03 PM
Analyst action: Healthways, AmSurg
Two local health care players who reported earnings last week were on the receiving end of a number of analyst moves Friday. On the one hand, Healthways was downgraded to 'neutral' by Madison Williams analyst James Kumpel, who also lowered his target for the shares. But at Noble Financial, Michael Petusky raised his opinion of Franklin-based Healthways to 'buy.' So far, Kumpel has the upper hand: Healthways shares (Ticker: HWAY) are down more than 3 percent today. Over at AmSurg, the news is more unequivocal: Both Noble's Petusky and Stifel Nicolaus' Rob Hawkins have downgraded the surgery center operator to 'hold' from 'buy.' Shares of AmSurg (Ticker: AMSG) have given up 8 percent since Friday morning. Apr 26, 2010 12:56 PM
Emdeon buys document converter
Nashville company will integrate technology into payment services division
Jan 26, 2010 8:22 AM
Medical messages
Is the growth potential of newly public Emdeon getting lost in translation? [From our print edition featured in Monday's City Paper]
Jan 25, 2010 12:43 AM
Analyst action: Dollar General, Pinnacle, Emdeon
A number of the investment banks who helped manage last month's Dollar General IPO have launched coverage of the retailer with mostly upbeat opinions. In addition the three mentioned in that link, Deutsche and Barclays Capital also have weighed in with 'buy' and 'overweight' ratings, respectively. Both of those firms see the stock (Ticker: DG) rising at least 24 percent. Pinnacle Financial Partners got a nice bump this morning from Keefe Bruyette analyst Jefferson Harralson, who has raised his rating on the bank to 'outperform' and lifted his target to $16.50 from $14.50. Pinnacle shares (Ticker: PNFP) were up 9 percent in early trading, but have since retreated a bit. At about 11:10, they were up more than 3 percent to $14.13. And at Madison Williams, analyst James Kumpel recently began covering Emdeon shares with a 'buy' rating and a target of $21, which is a whopping 40 percent above where they are trading this morning. Kumpel said the Nashville-based payment intermediary (Ticker: EM) is "the only true single-source solution for provider to manage healthcare transactions across virtually all payers" and will benefit from the increasing complexity of the health care system. Key to growth in the coming years is cross-selling, where the company sees more than $2 billion in opportunities. Dec 23, 2009 11:14 AM
